A major clinical study has produced compelling evidence for a new treatment approach in high-risk leukemia management. The QUIZOM combination therapy achieved an 83% complete remission rate in patients with FLT3-mutated acute myeloid leukemia—significantly outperforming existing treatment options.
For context, Quizartinib monotherapy achieved a 65% remission rate, while standard chemotherapy reached only 45%. Omacetaxine alone produced a 25% remission rate. This substantial performance gap underscores the advantage of the dual-mechanism approach developed by HKUMed researchers.
FLT3-mutated variants represent some of the most challenging blood cancers globally, with the World Health Organization estimating approximately 474,000 new leukemia cases annually. The improved remission rates achieved with QUIZOM combination therapy suggest a meaningful advancement in treatment outcomes for this high-risk patient population.
Read the full article on GMJ Newsroom.
Was this article helpful?
